Experimental Treatments

Abatacept is an injection and infusion therapy approved for other conditions that has been investigated to help control relapsing, non-severe granulomatosis with polyangiitis, a common form of AAV. The therapy was tested in a Phase 3 clinical trial that failed to meet its efficacy goals. Its future clinical development is currently unclear.

Benlysta (belimumab) is an approved therapy for lupus that is also being investigated to see if it can prevent flares or relapses in people with ANCA vasculitis. Benlysta is an antibody-based drug that blocks a chemical messenger in the blood known as BLyS or BAFF. As of 2019, the therapy was in Phase 3 testing for ANCA vasculitis.

Lixudebart is an experimental infusion therapy being developed by Alentis Therapeutics to manage serious kidney disease that arises as a complication of AAV.